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Abstract
Background: Growth hormone (GH) plays a role in the reg-
ulation of ovarian function but there are limited data in 
women with GH deficiency (GHD). Our aim was to evalu-
ate the features of polycystic ovarian syndrome (PCOS) in 
women with previous GHD.
Methods: Data of 22 adolescents previously GH-treated 
(group A) were compared with those of 22 women with 
classical PCOS (group B) and 20 controls (group C).
Results: Group A showed higher testosterone (p = 0.048) 
and prevalence of menstrual irregularities (p < 0.001) than 
group C. Compared to the group B, group A showed lower 
diastolic blood pressure (p = 0.004), degree of hirsutism 
(p = 0.005), testosterone (p = 0.003) and prevalence of polyc-
sytic ovaries (POC) morphology (p = 0.024), with higher 
HDL-cholesterol (p = 0.035) and 17-β-estradiol (p = 0.009).
Conclusions: Adolescents with previous GHD show a 
higher prevalence of PCOS than controls, but with milder 
metabolic and hormonal features than adolescents with 
classical PCOS. A careful long-term follow-up is advisable 
in these patients.
Keywords: GH deficiency; growth hormone (GH); polycys-
tic ovarian syndrome.
Introduction
The polycystic ovarian syndrome (PCOS) is a heterogene-
ous clinical entity that affects approximately 6%–8% of 
reproductive-aged women [1]. A number of growth factors, 
such as insulin, growth hormone (GH) and insulin growth 
factor (IGF) 1 and 2, play a role in the regulation of ovarian 
function [2–4]. GH exerts its effects on the ovarian func-
tion directly, by both gonadotropin-dependent and gon-
adotropin-independent actions, or by local production of 
IGF-1 [5, 6]. PCOS is highly prevalent in acromegaly and 
acromegalic women with PCOS have increased ovarian 
volume and PCO morphology compared to those without 
PCOS with a positive correlation between serum IGF-1 
levels and mean ovarian volume, suggesting that IGF-1 is 
one of the critical factors involved in the development of 
PCOS [7]. Consequently, the treatment of GH hypersecre-
tion in acromegaly seems to improve the ovarian func-
tion and to restore the reproductive dysfunction related to 
PCOS [8, 9]. Conversely, there are limited data on ovarian 
function in women affected by GH deficiency (GHD) and 
whether the GHD status is accompanied by ovarian dis-
turbance or the GH treatment may affect ovarian function 
and morphology is still unclear.
The aims of this study were to evaluate, in a cohort of 
young women previously treated with GH for GHD during 
childhood and not confirmed in the transition age, the 
prevalence, metabolic status and phenotype of PCOS and 
to compare their clinical and biochemical features with 
a group of women with classical PCOS without previous 
GHD.
Materials and methods
This is a prospective case-control study. For the purpose of the study 
we enrolled 54 consecutive patients (mean age 17.1±2.1 years) admit-
ted to the Section of Endocrinology of the University of Palermo.
The diagnosis of GHD was established by the clinical, auxo-
logical and biochemical criteria of the GH Research Society (20). At 
the time of GHD diagnosis the patients had a mean age of 8.8 years 
(range 7.4–10.1) and mean height of –2.28±1.0 SD. They showed a 
mean growth velocity of 3.4±1.4 cm/years (–2.4 SD), mean bone/
chronological age ratio of 0.81 (indicating a delay of bone maturation 
of at least 1 year) and low serum IGF-1 levels (–1.6±0.8 SD).
The GH secretion was assessed by arginine and glucagon 
 stimulation test. During the arginine test, blood samples were 
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obtained at 0, 30, 60, 90, 120 min after the administration of the stim-
ulus (arginine monohydrochloride: 0.5 g/kg up to 30 g given intra-
venously over 30 min) for GH measurements. During the glucagon 
test, blood samples were collected at 0, 30, 60, 90, 120, 150, 180 and 
240  min after the injection of 30 μg/kg (up to 1.000 μg) intramus-
cularly of glucagon (GlucaGen, NovoNordisk, Bagsvaerd, Denmark). 
GHD was demonstrated by failure of GH to respond to two stimuli 
with GH peaks below 10 μg/L. All patients were treated with GH for 
at least 36  months (mean duration of treatment 54 months; range 
42–66) and received GH once daily at bedtime with a pen injection 
system. In line with our internal fixed protocol, IGF-1 levels and the 
growth velocity have allowed us to determine the GH dose. The initial 
daily dose of GH was 0.025 mg/kg and it has been on average gradu-
ally increased by 0.002–0.003 mg/kg/day every 6 months (mean daily 
dose of 0.028 mg/kg from month 6 to 12; 0.031 mg/kg from month 12 
to 18; 0.033 mg/kg from month 18 to 24; 0.035 mg/kg from month 24 
to 36) to maintain IGF-1 levels within the normal range for age during 
the entire follow-up. We excluded from this analysis patients affected 
by multiple pituitary hormone deficiency or receiving other hormo-
nal replacement treatment.
GH treatment was stopped at the end of the linear growth when 
the height outcome in line with the genetic target was achieved, after 
approximately 12  months of the menarche, and the follow-up has 
been continued annually after the GH treatment discontinuation. 
During this follow-up all patients have been evaluated for regularity 
of menses, degree of clinical or biochemical hyperandrogenism (HA) 
and ovarian morphology. Unlike adult PCOS, there are no agreed upon 
diagnostic criteria for adolescent PCOS, although hyperandrogenae-
mia remains the sine qua non for its diagnosis [10]. For these reasons, 
in this study we used the well standardized adult criteria [11]. Follow-
ing the Rotterdam criteria, PCOS can be diagnosed when two of the 
following symptoms or signs are present: menstrual irregularity (MI) 
with  < 9 menstrual periods per year, HA either clinical or biochemical, 
and PCO morphology on pelvic ultrasonography, in the absence of 
other disorders known to cause the same symptoms or signs. Accord-
ing to this classification, 22/54 patients resulted affected by PCOS 
(group GHD-PCOS = group A). The clinical and biochemical findings 
of this subgroup of patients were compared with those of a group of 
22 women with classical PCOS, matched for age and BMI, without pre-
vious GHD diagnosis, recruited from a consecutive series of women 
of reproductive age followed up in our Outpatients Clinic for PCOS 
(group PCOS = group B). The following subjects were excluded from 
the study: women treated with clomiphene citrate, oral contracep-
tives, antiandrogens and drugs to control their appetite or insulin-sen-
sitizing drugs (metformin, pioglitazone and rosiglitazone) during the 
6 months prior to the first examination; women with hyperprolactine-
mia; patients with basal 17OH-progesterone ( 17OH-Pg)  levels  > 6.05 
nmol/L or  > 30.26 nmol/L at 60 min after 250 mg Synacthen (synthetic 
analog of adrenocorticotrophic hormone); women with dehydroepi-
androsterone sulfate (DHEA-S)  > 16.32 mmol/L, who, when screened 
with a computerized axial tomography scan, presented adrenal 
hyperplasia or adenoma or virilizing androgen-secreting neopla-
sias; women whose clinical and hormone evaluation (phenotype, 
increased 24 h free urinary cortisol, high cortisol levels after 1 mg of 
overnight dexamethasone) suggested Cushing’s syndrome.
At the time of hospitalization, all patients signed a consent 
form for the scientific use of their data after a full explanation of the 
purpose of the study. This study was approved by the Institutional 
Review Board of the Faculty of Medicine, University of Palermo 
and the identity of the participants remained anonymous during 
database analysis. The study complies with the World Medical Asso-
ciation Declaration of Helsinki regarding ethical conduct of research.
Study protocol
The following data were obtained from our database: age of 
menarche, body mass index (BMI), waist circumference (WC) and 
hip circumference (HC), systolic blood pressure (SBP) and diastolic 
blood pressure (DBP).
In all enrolled patients, in line with our internal protocol, we 
evaluated the metabolic profile with lipid profile [total cholesterol 
(TC), HDL-cholesterol (HDL), LDL-cholesterol (LDL), triglycerides 
(TG)], hemoglobin A1c (HbA1c), fasting glucose and insulin levels, 
IGF-1. These samples also served as the baseline for an oral glucose 
tolerance test (OGTT). Blood samples were collected every 30  min 
for 2  h for glucose and insulin measurements. The area under the 
curve (AUC) of glucose (AUCGLU) and insulin (AUCINS) during OGTT 
was calculated using the trapezoidal rule. As surrogate estimates of 
insulin sensitivity we considered the homeostasis model assessment 
estimate of insulin resistance (Homa-IR): [glycemia (mmol/L) × insu-
linemia (μU/mL)/22.5] [12] and the insulin sensitivity index (ISI), a 
composite index derived from the OGTT and validated by Matsuda 
and DeFronzo [10,000/glucose (mg/dL) × insulin (μU/mL) × glucose 
mean × insulin mean] [13]. The stimulated total insulin secretion was 
evaluated by AUCINS, while the oral disposition index (DIo) was used 
as index of the ability of the β-cell to regulate its insulin response 
to stimuli based on differences in insulin sensitivity. DIo was calcu-
lated at the time 0′ and 30′ during OGTT as described (18), using the 
following formula, where insulin levels are expressed in IU/mL and 
glucose levels in mmol/L: DIo = [Δ insulin 0′–30′/Δ glucose 0′–30′] × 1/
fasting insulin [14]. All subjects were also analyzed according to each 
criterion of the metabolic syndrome (MS) [15]. Visceral adiposity 
index (VAI) was calculated as described by Amato et al. [16]. Hormo-
nal status was assessed by the evaluation of follicle (FSH) and lutein-
izing (LH) stimulating hormones, 17-β-estradiol (E2), 17OH-Pg, total 
testosterone (TT), DHEA-S, Δ4androstenedione (Δ4), and prolactin 
(PRL) during the follicular phase (day-7 from the beginning of the last 
period). Serum progesterone (PG) level was determined in the luteal 
phase (between days 20 and 24 from the beginning of the last period). 
In all subjects we also evaluated the presence of clinical (hirsutism, 
acne or seborrhea) and biochemical HA. Hirsutism was defined as 
Ferriman-Gallwey (FG) score  > 8 [17].
Due to the limitations of defining androgen excess and the lack 
of normative data on the normal developmental fluctuations in tes-
tosterone levels during puberty, androgen concentrations should 
be considered elevated when they are persistently greater than 
the adult female normative values [18]. In this study, biochemical 
HA was arbitrarily established with an in-house range, as follows: 
TT  > 2.08 nmol/L, DHEA-S  > 11.69 mmol/L, Δ4  > 10.72 nmol/L, calcu-
lated on the basis of the 95th percentile upper limits of basal serum 
androgen normality in a group of 20 healthy eumenorrhoic Sicilian 
women without clinical HA and family history of PCOS, matched 
for age (mean age 17.1±1.5 years) and BMI (22.3±2.5 kg/m2), recruited 
consecutively among the medical and paramedical personnel of 
our Department and their relatives, and/or patients’ relatives. This 
group of girls was used as a control group (group C) for the hormonal 
parameters and PCOS-features after informed consent for the scien-
tific use of their data was obtained.
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All subjects underwent transvaginal pelvic ultrasound scan-
ning on a single occasion in the follicular phase, between days 5 and 
10 from the beginning of the last period using a 2.5–8 MHz vaginal 
probe transducer (General Electric LOGIQ 400MD, Milwaukee, WI, 
USA). Both ovaries were measured in the sagittal, transverse and cor-
onal planes. Ovaries were classified as polycystic using the threshold 
of  ≥ 25 follicles measuring 2–9 mm in diameter [19].
Hormone and biochemical assays
All hormones were measured in our laboratory using commercial kits. 
These included enzyme-linked immunosorbent assay (DRG Diag-
nostics, DRG Instruments GmbH, Germany) for FSH (mUI/mL), LH 
(mUI/mL), E2 (pg/mL), 17OH-PG (ng/mL), PG(ng/mL), prolactin (ng/
mL), TT (ng/mL), Δ4 (ng/mL; Arnika, Milan, Italy), insulin (mUI/L). 
Chemiluminescence assays were used for DHEA-S (μg/dL; Immulite, 
Diagnostic Products, Genoa, Italy) and serum SHBG (nmol/L; Immu-
lite, Diagnostic Products). Serum IGF-1 was assayed in the same labo-
ratory with the ELISA method (OCTEIA IGF-I kit, IDS Inc., Fountain 
Hills, AZ, USA). The sensitivity of the method was 1.9 μg/L. The nor-
mal range of IGF-1 levels (μg/L) was 146–415 (15–20 years). Total cho-
lesterol, HDL and TG were measured in our laboratory using standard 
assays. LDL cholesterol levels were calculated with Friedewald’s for-
mula. The conversion factors for the International System were the 
following: glucose (mg/dL vs. mmol/L: 0.0555), insulin (mUI/L vs. 
pmol/L: 6.945), total cholesterol (mg/dL vs. mmol/L: 0.0259), total 
testosterone (ng/mL vs. nmol/L: 3.467), DHEA-S (μg/dL vs. μmol/L: 
0.0272), Δ4 (ng/mL vs. nmol/L: 3.492), 17OH-Pg (ng/mL vs. nmol/L: 
3.026), FSH (mUI/mL vs. IU/L: 1), and LH (mUI/mL vs. IU/L: 1).
Statistical analysis
The Statistical Packages for Social Sciences SPSS version 17 
(SPSS Inc., Chicago, IL, USA) was used for data analysis. Baseline 
characteristics were presented as mean±standard deviation (SD) for 
continuous variables; rates and proportions were calculated for cat-
egorical data. The normality of distribution of the quantitative vari-
ables was assessed by the Kolmogorov-Smirnov test. The differences 
between the two groups of subjects (group GHD-PCOS and group 
PCOS) were evaluated by the Student’s t test for continuous variables 
with a normal distribution, by the Mann-Whitney U-test (non-para-
metric test) for continuous variables without normal distribution and 
by the χ2-test and Fisher’s exact test (when appropriate) for categori-
cal variables. Simple univariate correlations among continuous vari-
ables with normal distribution were determined by Pearson’s test. A 
p-value of 0.05 was considered statistically significant.
Results
Hormonal parameters and PCOS features
In Table 1 we showed the prevalence of each PCOS-feature 
in the two groups of patients (group A and B) and con-
trols (group C). Group A showed a lower prevalence of 
PCO  morphology on pelvic ultrasonography than group B 
(36.4% vs. 90.9%; p = 0.024), while no difference was found 
in the prevalence of MI (p = 0.635), clinical (p = 0.445) or 
biochemical HA (p = 0.388), as well as of complete PCOS-
phenotype (p = 0.183).
Both group A and B showed a higher prevalence of 
clinical (p < 0.001) and biochemical (p < 0.001) HA and of 
MI (p < 0.001) than control subjects, while no difference 
was found in PCO morphology between group A and C 
(p = 0.738).
The hormonal parameters of patients (group A and B) 
and controls (group C) are shown in Table 2. Group B 
Table 1: Prevalence of PCOS-features in patients grouped in group GHD-PCOS (group A), group PCOS (group B) and control group (group C).
 
 
GHD-PCOS (group A) 
n = 22
 
 
PCOS (group B) 
n = 22
 
 
Control group (group C) 
n = 20
  p-Value   p-Valuea   p-Valueb
Subjects (%) Subjects (%) Subjects (%)
Hyperandrogenism            
 Clinical   16 (72.7)   20 (90.9)   0   0.445    < 0.001    < 0.001
  Hirsutism   10 (45.4)   18 (81.8)     0.183   –   –
  Acne/seborrhea   12 (54.5)   14 (63.6)   –   1   –   –
 Biochemical   6 (27.2)   14 (63.6)   0   0.388    < 0.001    < 0.001
  High TT levels   0   2 (9.1)   –   1   –   –
  High DHEA-S levels  2 (9.1)   2 (9.1)   –   1   –   –
  High Δ4 levels   4 (18.2)   10 (45.5)   –   0.361   –   –
MI   18 (81.8)   12 (63.6)   0   0.635    < 0.001    < 0.001
PCO   8 (36.4)   20 (90.9)   7 (35)   0.024   0.738   12
Complete phenotype 
(HA+MI+PCO)
  7 (31.8)   12 (54.5)   0   0.183    < 0.001    < 0.001
HA, Hyperandrogenism; TT, total testosterone; DHEA-S, dehydroepiandrosterone sulfate; Δ4, Δ4androstenedione; MI, menstrual 
 irregularity; PCO, polycystic ovaries on pelvic ultrasonography. p = Difference between group A and group B. ap = Difference between group A 
and group C. bp = Difference between group B and group C.
4      Ciresi et al.: Polycystic ovarian syndrome and growth hormone deficiency
Table 2: Hormonal parameters of patients grouped in group GHD-PCOS (group A), group PCOS (group B) and control group (group C).
 
 
GHD-PCOS (group A) 
n = 22
 
 
PCOS (group B) 
n = 22
  Control group (group C) 
n = 20
  p-Value   p-Valuea   p-Valueb
Mean±SD Mean±SD Mean±SD
FSH, IU/L   4.5±1.7   6±2.6   4.8±1.4   0.178   1   0.224
LH, IU/L   8.6±5.7   8±4.5   8.4±4.4   0.870   0.980   0.650
LH/FSH ratio   1.9±1   1.4±0.8   1.7±0.9   0.158   0.445   0.238
17-β-E2, pg/mL   58.5±24.8   39.5±16.6   55.7±28.2   0.009   0.766   0.007
17OHPg, nmol/L   1.3±0.6   1.4±0.9   1.3±0.5   1   1   0.980
Pg, ng/mL   5±6.7   5.1±5.2   5±6.5   0.888   0.890   0.870
PRL, ng/mL   15.9±9.8   11.3±6.6   10.7±8.1   0.139   0.122   0.545
Total testosterone, nmol/L   1.4±0.4   2±0.5   0.8±0.3   0.003   0.048   0.002
DHEA-S, μmol/L   6.8±3.1   7.8±3.3   6.9±4.2   0.450   0.755   0.520
Δ4androstenedione, nmol/L  9.6±7.1   10.2±5.4   9.5±7.4   0.669   0.868   0.702
IGF-1, μg/L   245±38.2   290±28   287.1±33.6   0.445   0.580   0.860
p = Difference between group A and group B. ap = Difference between group A and group C. bp = Difference between group B and group C.
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showed lower E2 (39.5±16.6 vs. 58.5±24.8 and 55.7±28.2 
pg/mL; p = 0.009 and p = 0.007, respectively) and higher 
TT (2±0.5 vs. 1.2±0.4 and 1.1±0.8 nmol/L; p = 0.003 and 
p = 0.002, respectively) than group A and group C, while no 
difference was found in others hormonal parameters. No 
difference was found in all hormonal parameters between 
group A and C, with the exception of higher TT levels in 
group A than C (1.4±0.4 vs. 0.8±0.3 nmol/L; p = 0.048).
Clinical and metabolic parameters
The clinical and metabolic features of patients are shown 
in Table 3.
The mean age (17.2±2.7 vs. 17.6±1.2 years; p = 0.615) and 
BMI (22.2±3.7 vs. 22.6±2.7 kg/m2; p = 0.818) were compara-
ble in both groups of patients. Similarly, no difference was 
found in WC and HC. Group A showed lower DBP (56.3±6.7 
vs. 67.2±7.8 mmHg; p = 0.004) and FG score (8±3.1 vs. 14.2±5.4; 
p = 0.005) than group B, while no difference was shown in SBP 
(100.9±10.2 vs. 110±10.9 mmHg; p = 0.051). As regards the met-
abolic parameters, group A showed higher HDL-cholesterol 
than group B (1.7±0.3 vs. 1.4±0.3 mmol/L; p = 0.035), while no 
significant difference was found in the others parameters 
evaluated. Using the above mentioned criteria of MS [15], 
no patients showed the presence of MS as a whole and we 
have not found a statistical difference in each of the compo-
nents of MS between the two groups of patients. Only two 
patients (9.1%) of group A showed hypertriglyceridemia, two 
patients (9.1%) of group B showed impaired fasting glucose, 
while two patients (9.1%) of group A and six patients (27.3%) 
of group B showed low HDL-cholesterol. No patient showed 
systolic or diastolic hypertension or increased WC.
Discussion
To our knowledge, this is the first study that investigates 
the PCOS phenotype in patients with previous GHD. The 
results of this study reveal a high prevalence of PCOS in 
this group of women previously treated with GH, but with 
milder metabolic and hormonal features than the classi-
cal PCOS.
During the transition from adolescence to adulthood 
it is well known that several PCOS-features may be in evo-
lution or transitory. The classic signs and symptoms of MI 
and HA seen in adults are not as clear in adolescents as 
the physiology of normal puberty may mimic PCOS and 
most authors agree that applying criteria for adults to ado-
lescents can lead to over-diagnosis because of similarity in 
physiological changes during puberty and common PCOS 
symptoms [20, 21]. Indeed, approximately 40%–50% of 
adolescent girls have anovulatory cycles. In addition, 
some girls could show multifollicular ovaries as a stage of 
development and it may be misinterpreted. Further, if the 
ovary has features of polycystic morphology but does not 
meet the recommended volumetric criteria, the diagnosis 
of PCOS should not be ascribed on this basis. In this study 
we found in GHD-PCOS group a similar prevalence of HA 
and MI than PCOS-group, but higher than control subjects. 
Conversely, in both GHD-PCOS and controls we found a 
lower prevalence of PCO morphology. Actually, there are 
limited data that suggest the relationship between GHD 
and ovarian disturbance. It has been already suggested 
that some disturbance in reproductive function can be 
expected in women treated for GHD during childhood 
[22], while GHD as a cause for delayed puberty or primary 
amenorrhea has also been hypothesized [6,  23]. In line 
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Table 3: Clinical and metabolic features of patients grouped in group GHD-PCOS (group A) and group PCOS (group B).
 
 
GHD-PCOS (group A) 
n = 22
 
 
PCOS (group B) 
n = 22
  p-Value
Mean±SD Mean±SD
Age, years   17.2±2.7  17.6±1.2  0.615
Age of menarche, years   12.7±1.3  12±1.1  0.200
BMI, kg/m2   22.2±3.7  22.6±2.7  0.818
Waist circumference, cm   76.3±6.7  75.9±11.1  0.669
Hip circumference, cm   89.6±6.5  95.9±11.8  0.188
Waist/hip circumference ratio   0.85±0.08  0.79±0.07  0.053
Systolic blood pressure, mmHg   100.9±10.2  110±10.9  0.051
Diastolic blood pressure, mmHg   56.3±6.7  67.2±7.8  0.004
FG score   8±3.1  14.2±5.4  0.005
Fasting glucose, mmol/L   4.4±0.2  4.5±0.4  0.621
AUCGLU (OGTT), mmol/L   651±116  701±154  0.577
Fasting insulin, pmol/L   12.3±5.3  13.3±6.4  0.793
AUCINS (OGTT), pmol/L   7929±5658  9945±5687  0.061
HbA1c, %   4.8±0.4  5±0.3  0.661
Homa IR   2.4±1.1  2.6±1.2  0.768
ISI Matsuda   5.2±2.2  4.2±1.7  0.200
Dio   6.4±7  5.2±6.3  0.870
Total cholesterol, mmol/L   4.3±0.6  4.7±1.1  0.459
HDL cholesterol, mmol/L   1.7±0.3  1.4±0.3  0.035
LDL cholesterol, mmol/L   84.8±16  110.9±45.7  0.453
Triglycerides, mmol/L   2.1±0.8  2.2±0.8  0.511
Visceral adiposity index   1±0.4  1.3±0.6  0.412
  Subjects (%)   Subjects (%)  
Metabolic syndrome   0  0  –
Increased waist circumference   0  2 (9.1)  1
Hypertriglyceridemia   2 (9.1)  0  1
Low HDL cholesterol   2 (9.1)  6 (27.3)  0.586
Increased SBP or DBP   0  0  –
Hyperglycemia   0  2 (9.1)  1
OGTT, Oral glucose tolerance test; FG, Ferriman-Gallwey; Dio, oral disposition index; SBP, systolic blood pressure; DBP, diastolic blood pressure.
with these evidences, in our study the previous GHD con-
dition may have been the cause of the differences between 
the two groups of patients and these data are partially in 
line with previous studies. Indeed, De Boer et al. showed 
in 60 GHD women who had been treated for GHD during 
childhood that about 56% showed no spontaneous puber-
tal development and among the women who did, only half 
showed regular menstrual cycles, while the remaining 
showed secondary amenorrhea or oligomenorrhea after 
discontinuation of GH [22].
In the current study, although the age of menarche 
was not significantly different between the two groups of 
women, we found that about 81% of women of the GHD-
PCOS group had MI and this finding is not different from 
that observed in PCOS-group, but it is higher than both 
our healthy controls and the general population age-
matched, where chronic anovulation and MI are evident 
in approximately 40%–50% [24].
The Endocrine Society Clinical Practice Guidelines 
suggested that the diagnosis of PCOS in adolescents is 
based on the presence of clinical and/or biochemical HA in 
the presence of persistent oligomenorrhoea, while anovu-
latory symptoms and PCO morphology were deemed insuf-
ficient to make a diagnosis in adolescents [25]. Despite 
these findings, there is no overall consensus regarding 
the diagnosis of PCOS in adolescents. Currently it seems 
justifiable to diagnose PCOS in adolescents using the Rot-
terdam criteria, on condition that all three symptoms are 
present, HA is established in laboratory tests and pelvic 
ultrasound meets clear morphological criteria [19, 26, 27]. 
In line with these criteria, when the diagnosis was made 
by the presence of the complete phenotype, we found a 
higher prevalence of PCOS in girls with previous GHD than 
control subjects. These data are confirmed if we consider a 
recent epidemiological survey on the prevalence of PCOS-
features in late adolescent and young women performed 
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by Gambineri et al. that showed a prevalence of MI of 10%–
13%, clinical HA of about 16% and PCOS of  < 15% [28]. To 
explain our data of prevalence the relationship between 
GH-IGF-1 axis and ovarian morphology and function must 
be taken into account. It is well established that GH pro-
motes sexual maturation and reproductive function [29]. 
On the other hand, ovarian dysfunction is often associated 
with altered GH secretion and anovulatory women often 
show lower GH pulses [30, 31], as well as women with PCOS 
can manifest a blunted GH secretion after GHRH stimula-
tion [32, 33]. To evaluate the impact of the previous GHD 
condition or GH treatment on the metabolic and hormonal 
features of PCOS in these patients we compared them to a 
group of age-matched women with classical PCOS without 
previous GHD. These latter showed worse metabolic and 
hormonal parameters than the GHD-PCOS group. Higher 
blood pressure values and a worse lipid profile were found 
in classical PCOS than in GHD-PCOS women. These data 
are not surprising because the metabolic impairment in 
women with PCOS is well known [34–36], although a limi-
tation of this study can be represented by the “non-obese” 
population in both groups of patients.
Similarly, the hormonal assessment and ovarian 
morphology were found worse in classical PCOS than 
in women with previous GHD, as showed by higher TT 
and lower E2 levels in the first group and by the con-
comitant higher prevalence of PCO morphology. Con-
versely, GHD-PCOS women showed a higher prevalence 
of MI and higher TT levels, with a consequent higher 
prevalence of clinical and biochemical HA, than healthy 
controls and these data lead to the higher prevalence of 
 PCOS-phenotype observed in the patients of group A. 
These findings can lead to hypothesize the effect of GH 
therapy on the ovarian morphology and function. Indeed, 
the involvement of GH in the control of sexual maturation 
and gonadal growth and function, through both autocrine 
and paracrine effects, is well known [37–39] and a role of 
GH and IGF-1 in activating the ovarian androgen produc-
tion has been shown [40, 41]. In addition, exogenous GH 
has been demonstrated to increase the concentration of 
testosterone [42] and these data are in line with our find-
ings. Conversely, we can speculate that the presence of 
softer metabolic and hormonal features in the GHD-PCOS 
group than classical PCOS may be dependent on the pre-
vious condition of GHD, probably not treated from the 
real onset of the hormonal deficit but only from the time 
of the diagnosis. These data, with the concomitant higher 
evidence of MI in GHD-PCOS than healthy subjects, can 
be considered as a result of the delayed or reduced effect 
of GH on the ovarian maturation and function, probably 
destined to weaken over time.
In conclusion, the adolescents previously treated with 
GH for childhood GHD show a higher prevalence of PCOS 
than healthy subjects, but with milder features than adoles-
cents with classical PCOS and it can be assumed that these 
findings may be due both to the previous lack of GH effects 
and to the subsequent effect of GH therapy. Given that it 
is known that during puberty the features of PCOS overlap 
normal pubertal development and caution should be taken 
before diagnosing PCOS without longitudinal evaluation, 
and given the well-known relationship between GH axis 
and ovarian morphology and function, in adolescents with 
a previous diagnosis of GHD who underwent GH treatment 
it is advisable to maintain a careful clinical follow-up after 
discontinuation of GH treatment to evaluate any hormonal 
or phenotypic change that can allow to review the eventual 
diagnosis of PCOS in these patients.
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